Zydus Lifesciences Limited has informed the Exchange regarding a press release dated February 27, 2026, titled "Zydus Lifesciences announces successful clinical development of Pembrolizumab biosimilar FYB206, marking a milestone toward USFDA filing".
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Zydus Lifesciences announced that the pivotal Dahlia pharmacokinetic (PK) study for FYB206, its proposed biosimilar of Merck's blockbuster cancer drug Keytruda (pembrolizumab), successfully met its primary study objective by demonstrating bioequivalence with the original drug. FYB206 was in-licensed from Germany's Formycon AG for the U.S. and Canadian markets. With the clinical data package now effectively complete, the company is positioned to file a Biologics License Application (BLA) with the USFDA in the near term. Zydus could become a potential first-wave filer in the North American immuno-oncology biosimilar market. Keytruda, the reference drug, posted global sales of US$ 31.6 billion in 2025, underlining the scale of the opportunity.
Positive medium-to-long-term signal for shareholders — Zydus is positioning itself for entry into a multi-billion-dollar oncology market in North America with a first-mover biosimilar advantage. However, this is still a pre-filing milestone; actual revenue depends on USFDA approval, launch timing relative to Keytruda's patent expiry, and competitive dynamics among other biosimilar developers.